Global Chronic Bronchitis Market, By Treatment Type (Pharmacological, Nonpharmacological, Others), Drug Class (Bronchodilators, Glucocorticoids, Antibiotic, Phosphodiesterase-4 Inhibitors, Others), Route of Administration (Oral, Parenteral Inhalational, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.
Chronic Bronchitis Market Analysis and Size
The global chronic bronchitis market is expected to witness significant growth during the forecast period. Rising prevalence of allergic reactions worldwide and emerging markets are the factors responsible for the growth of this market. Growing cases of asthma and COPD which causes severe coughing problem drives the chronic bronchitis market. The market growth is expanding and is expected to rise high in the forecast period.
Data Bridge Market Research analyses a growth rate in the global chronic bronchitis market in the forecast period 2022-2029. The expected CAGR of global chronic bronchitis market is tend to be around 4.0% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Chronic bronchitis is inflammation with long-term swelling and irritation in the air passages. Over the time symptoms get worsen and causes serious lungs damage and sometime its permanent. The cough lasting from three months occurs within a life span of 2 years. Chronic bronchitis is majorly associated with smoking and type of chronic obstructive pulmonary disease (COPD).
Chronic Bronchitis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment Type (Pharmacological, Nonpharmacological, Others), Drug Class (Bronchodilators, Glucocorticoids, Antibiotic, Phosphodiesterase-4 Inhibitors, Others), Route of Administration (Oral, Parenteral Inhalational, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bayer AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceutical PLC (U.S.), Amneal Pharmaceuticals LLC. (U.K.), Aurobindo Pharma (India), Johnsons & Johnsons Private limited (U.S.) and GlaxoSmithKline Plc (U.S.)
|
|
Market Opportunities
|
|
Global Acute Bronchitis Market Dynamics
Drivers
- Increasing Prevalence of COPD
Increased prevalence of COPD is a major factor driving the market growth. As per a June 2021 update WHO, chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing burden of COPD is leading to increasing demand for chronic bronchitis treatment.
- Growing Demand for Combination Therapy
Adoption of combination therapy is surging, as it is more effective than the separate use of bronchodilator and corticosteroid. Rise in number of patients being successfully treated with combination therapy, who were devoid of signs of recovery with bronchodilators or corticosteroids treatments, is expected to prompt the global chronic obstructive pulmonary disease treatment market.
Opportunities
- Rising Prevalence of Smoking
Smoking is one of the leading cause of mortality in the U.S., resulting for more than 480,000 deaths every year. Cigarette smoking was noticed to be highest among people between the age group of 25–44 years and 45–64 years. Thus, in return it leads to chronic bronchitis and create opportunities for the market growth.
- Advanced Clinical Research and Innovative Strategies
Many market players are involved in the adaptation of strategic initiatives, hence contributing to market growth. For instance, the U.S. FDA approved Brovana for treating bronchoconstriction in chronic obstructive pulmonary disease (COPD) patients in February 2022. The active agent in Brovana is a bronchodilator which is a substance that prompts the airways to relax and widen, thus lessening bronchoconstriction.
Restraints/Challenges
- Lack of Awareness
Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.
- High Cost
The huge expenditure required for treating chronic bronchitis surely hamper the market growth.
This global chronic bronchitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chronic bronchitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Chronic Bronchitis Market Scope
The global chronic bronchitis market is segmented on the basis of treatment type, drug class, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Pharmacological
- Nonpharmacological
- Others
Drug Class
- Bronchodilators
- Glucocorticoids
- Antibiotic
- Phosphodiesterase-4 Inhibitors
- Others
Route of Administration
- Oral
- Parenteral Inhalational
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospitals
- Specialty Clinics
- Others
Chronic Bronchitis Market Regional Analysis/Insights
The global chronic bronchitis market is analysed and market size insights and trends are provided by treatment type, drug class, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the global chronic bronchitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America holds the largest market share due to increasing infection in geriatric population, and growing population with smoking habits.
Asia-Pacific is expected to account for the largest market share over coming years for the Chronic bronchitis market due to increased prevalence of COPD, asthma and other lungs diseases and increasing initiatives taken by the government and pharmaceutical organizations to spread awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chronic Bronchitis Market Share Analysis
The global chronic bronchitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chronic bronchitis market
Key players operating in the global chronic bronchitis market include:
- Bayer AG (Germany
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Hikma Pharmaceutical PLC (U.S.)
- Amneal Pharmaceuticals LLC. (U.K.)
- Aurobindo Pharma (India)
- Johnsons & Johnsons Private limited (U.S.)
- GlaxoSmithKline Plc (U.S.)
SKU-